Arcadia Biosciences Files 8-K/A Amendment on Director Changes
Ticker: RKDA · Form: 8-K/A · Filed: Aug 23, 2024 · CIK: 1469443
| Field | Detail |
|---|---|
| Company | Arcadia Biosciences, Inc. (RKDA) |
| Form Type | 8-K/A |
| Filed Date | Aug 23, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $260,000, $212,063, $2.71 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, board-of-directors, executive-compensation
TL;DR
Arcadia Biosciences amended its 8-K filing to update board and executive compensation details.
AI Summary
Arcadia Biosciences, Inc. filed an amendment (8-K/A) on July 2, 2024, to report changes in its board of directors and executive compensation arrangements. The filing specifically addresses the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for key executives.
Why It Matters
This amendment provides crucial updates on the company's leadership and governance structure, which can impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Amendments to board composition and executive compensation can signal internal changes that may affect future performance or strategy.
Key Numbers
- 001-37383 — SEC File Number (Identifies the company's filing history with the SEC.)
- 81-0571538 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Arcadia Biosciences, Inc. (company) — Registrant
- July 02, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 214 974-8921 (phone_number) — Registrant's Telephone Number
FAQ
What specific items are being amended in this 8-K/A filing?
This amendment addresses the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
What is the earliest event date reported in this filing?
The earliest event date reported is July 02, 2024.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the principal executive office address listed?
The principal executive office is located at 5950 Sherry Lane Suite 215, Dallas, Texas, 75225.
What is the filing type and amendment number?
The filing type is a CURRENT REPORT on FORM 8-K/A, specifically Amendment No. 1.
Filing Stats: 1,492 words · 6 min read · ~5 pages · Grade level 11.5 · Accepted 2024-08-23 11:56:46
Key Financial Figures
- $260,000 — base salary as of the Effective Date as $260,000 per annum and his 2024 target bonus opp
- $212,063 — base salary as of the Effective Date as $212,063 per annum and his 2024 target bonus opp
- $2.71 — common stock with an exercise price of $2.71 per share. Mr. Schaefer's and Mr. Kawak
Filing Documents
- rkda-20240702.htm (8-K/A) — 50KB
- rkda-ex10_1.htm (EX-10.1) — 226KB
- rkda-ex10_2.htm (EX-10.2) — 217KB
- img5370606_0.jpg (GRAPHIC) — 66KB
- img5370606_1.jpg (GRAPHIC) — 17KB
- img6294127_0.jpg (GRAPHIC) — 66KB
- img6294127_1.jpg (GRAPHIC) — 17KB
- 0000950170-24-100065.txt ( ) — 894KB
- rkda-20240702.xsd (EX-101.SCH) — 25KB
- rkda-20240702_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1+ Employment Letter and Severance and Change In Control Agreement for Thomas J. Schaefer. 10.2+ Employment Letter and Severance and Change In Control Agreement for Mark Kawakami. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). + Represents a compensatory plan or arrangement.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCADIA BIOSCIENCES, INC. Date: August 23, 2024 By: /s/ MARK KAWAKAMI Mark Kawakami, Chief Financial Officer